Moderna agreed to a multi‑hundred‑million dollar settlement with Arbutus Biopharma and Roivant/Genevant to resolve long‑running patent litigation over lipid nanoparticle (LNP) delivery technology. Moderna will pay $950 million upfront and face up to $1.3 billion more contingent on a pending appeal over government‑contract immunity, while receiving a global non‑exclusive license for infectious‑disease uses. The settlement resolves suits across multiple jurisdictions that centered on the fatty‑shell LNPs used to deliver mRNA in Spikevax. Genevant and Arbutus will license their LNP patents to Moderna under the agreement, and Roivant’s executives framed the deal as recognition of their role in pandemic vaccine delivery. Moderna acknowledged infringement in the litigation filings while stressing the conditional nature of part of the payout tied to an appeal under 28 U.S.C. §1498. Stéphane Bancel, Moderna’s CEO, said the deal “removes uncertainty” and lets the company focus on near‑term growth plans. For industry readers: the outcome settles a major intellectual‑property dispute over a foundational platform technology for mRNA vaccines and may change how companies price litigation risk, license LNPs and structure future platform partnerships.